Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Francesco Boccalatte(Candiolo Cancer Institute), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)

Cancers

October 18, 2022

10.3390/cancers14205108

Cited by 23

Related Papers

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

|Blood|2003|407

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

|JAMA|2011|320

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

|Blood|2011|268

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma

|Biology of Blood and Marrow Transplantation|2008|264

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

|Journal of Clinical Oncology|2013|212